Our Awards
and Ratings

Our Ratings

Recommended Rating from Lonsec Research 2026

  • The Atrium Evolution Series – Diversified Fund
  • MAPS Risk Targeted 5 Portfolio
  • MAPS Risk Targeted 7 Portfolio
  • MAPS Risk Targeted 9 Portfolio
  • MAPS Balanced Opportunities Portfolio
  • MAPS Growth Opportunities Portfolio

Our Awards

Multi-Asset Flexible Asset Allocation 2022

Atrium won the Multi-Asset Flexible Asset Allocation category of the 2022 Financial Standard Investment Leadership Awards for the second consecutive year.

Lonsec Manager of the Year Finalist 2022

Our Atrium Evolution Series – Diversified Fund AEF 9 was nominated in the Lonsec Multi-Asset Fund of the Year category of the 2022 Lonsec and SuperRatings Fund of the Year Awards, which recognises the best in the wealth management and superannuation industries.

Multi-Asset Flexible Asset Allocation 2021

Atrium won the 2021 Financial Standard Investment Leadership Award in the Multi-Asset Flexible Asset Allocation category. These awards aim to recognise outstanding investment managers across major asset classes.

Awards & Ratings Information

Ratings are only one factor to be taken into account when deciding whether to invest in a financial product. The ratings published on 04/2026 for Atrium Evolution Risk Targeted – AEF 5, on 04/2025 for Atrium Evolution Risk Targeted – AEF 7, on 04/2026 for Atrium Risk Targeted  – AEF 7 P, on 04/2026 for Atrium Evolution Risk Targeted – AEF 9, and on 04/2026 for Atrium Evolution Risk Targeted – AEF 9 P are issued by Lonsec Research Pty Ltd (ABN 11 151 658 561, AFSL 421445) (Lonsec Research). The ratings published on 06/2026 for MAPS Risk Targeted 5 Portfolio, on 06/2026 for MAPS Risk Targeted 7 Portfolio, on 06/2026 for MAPS Risk Targeted 9 Portfolio, on 06/2026 for MAPS Balanced Opportunities Portfolio, and on 06/2026 for MAPS Growth Opportunities Portfolio are issued by Lonsec Research. Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the relevant PDS and TMD and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec Research assumes no obligation to update. Lonsec Research uses objective criteria and receives a fee from the fund manager. Visit www.lonsec.com.au for ratings information and to access the full report. 2026 Lonsec. All rights reserved.

Important Information

This information has been prepared and issued by Atrium Investment Management Pty Ltd (ABN 17 137 088 745, AFSL 338 634) (Atrium) as the investment manager of the Marketing Name: Atrium Evolution Risk Targeted Fund. Registered Name: Atrium Evolution Series – Diversified Fund (ARSN151 191 776), Integrated Managed Account Portfolio Service (ARSN 627 688 402) (MAPS) and the Colonial First State Separately Managed Account (ARSN 618 390 051) (CFS SMA).

The information is general information only and is not intended to provide you with financial advice and has been prepared without taking into account your objectives, financial situation or needs. You should consider the product disclosure statement (PDS), prior to making any investment decisions. The PDS and target market determination (TMD) can be obtained by visiting our website atriuminvest.com.au. If you require financial advice that takes into account your personal objectives, financial situation or needs, you should consult your licensed or authorised financial adviser. his information is only as current as the date indicated, and may be superseded by subsequent market events or for other reasons. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. All investments contain risk and may lose value.

The Trust Company (RE Services) Limited (ABN 45 003 278 831, AFSL 235150) is the Responsible Entity (RE) of the Atrium Evolution Series – Diversified Fund (ARSN 151 191 776), Integrated Managed Account Portfolio Service (ARSN 627 688 402) (MAPS), Atrium Enhanced Fixed Income Fund (ARSN 616 127112) and Atrium Alternatives Fund (ARSN 616 126 982). Investors should consider the PDS and TMD (available from Atrium’s website) before making any investment decisions.

Colonial First State Investments Limited (ABN 98 002 348 352, AFSL 232468 ) is the Responsible Entity (RE) of the Colonial First State Separately Managed Account (ARSN 618 390 051) (CFS SMA). Atrium is the portfolio manager of each of the aforementioned portfolios. Investors should consider the relevant offering document (Product Disclosure Statement (PDS) or Information Memorandum (IM) as appropriate), Target Market Determination (TMD) and other relevant information available from Atrium before making any investment decision. Investments in the CFS SMA are only available on CFS Edge. Investors should consider the PDS and TMD before making any investment decisions. Applications for a portfolio in the CFS SMA can only be made pursuant to the application form attached to the relevant PDS or Investor Directed Portfolio Service (IDPS) guide (CFS SMA Offer Documents). Please refer to the CFS SMA Offer Documents for important information concerning an investment in the CFS SMA.

You can only invest in MAPS through HUB24 Invest, an IDPS operated and administered by HUB24 Custodial Services Ltd (ABN 94 073 633 664, AFSL239122) (HUB24 Custodial Services), or through HUB24 Super, a super investment service offered through the HUB24 Super Fund (ABN 60 910 190 523, RSER1074659, USI 60 910 190 523 001) (‘Nominated Platform’ means either HUB24 Invest or HUB24 Super). HUB24 Custodial Services is the promoter of theHUB24 Super Fund and provides a range of services to the HUB24 Super Fund. Investors should consider the MAPS PDS and TMD (available from the Nominated Platform’s and Atrium’s website) before making any investment decision. Please refer to the disclosure documents for your Nominated Platform(available from your financial adviser or your Nominated Platform) together with the PDS for important information concerning an investment in MAPS.

Search for